Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
H.R. 1 (tax policy including changes to corporate tax structure) Tax codes that ensure investment in research & development of novel treatments for patients.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2017 · fourth_quarter · Q4
Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug Compounding and the Drug Quality and Security Act of 2013 Drug Importation/Counterfeit Drugs.
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
Source: Senate LDA
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
Helping Families in Mental Health Crisis Act of 2016
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016.
Helping Families in Mental Health Crisis Act of 2016
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Helping Families in Mental Health Crisis Act of 2016
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.
Helping Families in Mental Health Crisis Act of 2016
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Helping Families in Mental Health Crisis Act of 2016
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.
Helping Families in Mental Health Crisis Act of 2016
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.
Eliminating the Hidden Student Loan Tax Act
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Eliminating the Hidden Student Loan Tax Act
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Great Lakes Ecological and Economic Protection Act of 2015
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Great Lakes Ecological and Economic Protection Act of 2015
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Great Lakes Ecological and Economic Protection Act of 2015
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
Great Lakes Ecological and Economic Protection Act of 2015
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
Stop Tampering of Prescription Pills Act of 2013
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Stop Tampering of Prescription Pills Act of 2013
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Prescription Drug Abuse Prevention and Treatment Act of 2013
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Prescription Drug Abuse Prevention and Treatment Act of 2013
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Preserve Access to Affordable Generics Act
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
Preserve Access to Affordable Generics Act
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug.
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug.
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug.
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Stop Tampering of Prescription Pills Act of 2013
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Stop Tampering of Prescription Pills Act of 2013
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Stop Tampering of Prescription Pills Act of 2013
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Prescription Drug Abuse Prevention and Treatment Act of 2013
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Prescription Drug Abuse Prevention and Treatment Act of 2013
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Prescription Drug Abuse Prevention and Treatment Act of 2013
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Preserve Access to Affordable Generics Act
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
Preserve Access to Affordable Generics Act
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
Preserve Access to Affordable Generics Act
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
Prescription Drug Abuse Prevention and Treatment Act of 2013
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Prescription Drug Abuse Prevention and Treatment Act of 2013
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Prescription Drug Abuse Prevention and Treatment Act of 2013
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
H.R. 1 (tax policy including changes to corporate tax structure) Tax codes that ensure investment in research & development of novel treatments for patients.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.
Access to appropriate mental health care treatments across the U.S. Creating access to Long Acting Reversible Contraceptives for patients in areas impacted by the Zika virus. Supporting investment in safe, quality, accessible, and affordable biopharma products. Ensuring level and appropriate penalties for those harming patients by illegally diverting and counterfeiting pharmaceutical products.
Ensuring drug safety and efficacy gold standards at appropriate regulatory agency. Bioequivalence issues with non-biologic complex drugs. Protecting patients from illegally diverted/counterfeited medicines.
Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines. Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.
Intellectual property protections for novel therapies to treat crucial medical needs. Patent reform proposals. Hatch-Waxman Implications of the Inter Partes Review Process.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2017 · third_quarter · Q3
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.
Intellectual property protections for novel therapies to treat crucial medical needs. Patent reform proposals. Hatch-Waxman Implications of the Inter Partes Review Process.
Access to appropriate mental health care treatments across the U.S. Creating access to Long Acting Reversible Contraceptives for patients in areas impacted by the Zika virus. Supporting investment in safe, quality, accessible, and affordable biopharma products. Ensuring level and appropriate penalties for those harming patients by illegally diverting and counterfeiting pharmaceutical products.
Tax policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines. Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.
Ensuring drug safety and efficacy gold standards at appropriate regulatory agency. Bioequivalence issues with non-biologic complex drugs. Protecting patients from illegally diverted/counterfeited medicines.
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug Compounding and the Drug Quality and Security Act of 2013 Drug Importation/Counterfeit Drugs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2017 · second_quarter · Q2
Tax policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Access to appropriate mental health care treatments across the U.S. Creating access to Long Acting Reversible Contraceptives for patients in areas impacted by the Zika virus. Supporting investment in safe, quality, accessible, and affordable biopharma products. Ensuring level and appropriate penalties for those harming patients by illegally diverting and counterfeiting pharmaceutical products.
Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug Compounding and the Drug Quality and Security Act of 2013 Drug Importation/Counterfeit Drugs.
Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines. Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
Intellectual property protections for novel therapies to treat crucial medical needs. Patent reform proposals.
Ensuring drug safety and efficacy gold standards at appropriate regulatory agency. Bioequivalence issues with non-biologic complex drugs. Protecting patients from illegally diverted/counterfeited medicines.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2017 · first_quarter · Q1
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.
Access to appropriate mental health care treatments across the U.S. Creating access to Long Acting Reversible Contraceptives for patients in areas impacted by the Zika virus. Supporting investment in safe, quality, accessible, and affordable biopharma products. Ensuring level and appropriate penalties for those harming patients by illegally diverting and counterfeiting pharmaceutical products.
Intellectual property protections for novel therapies to treat crucial medical needs. Patent reform proposals.
Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines. Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.
Ensuring drug safety and efficacy gold standards at appropriate regulatory agency. Bioequivalence issues. Protecting patients from illegally diverted/counterfeited medicines.
Tax policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.
Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug Compounding. Drug Importation/Counterfeit Drugs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · fourth_quarter · 4A
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace
Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation. Promoting the social contract with patients to ensure they have affordable access to critical innovative medicines.
Patent Reform Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.
Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.
Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.
Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases. Protecting patients from demonstrations, regulations, and rules that would limit access to life-saving medicines.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · fourth_quarter · 4A
Patent Reform Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases. Protecting patients from demonstrations, regulations, and rules that would limit access to life-saving medicines.
Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · third_quarter · 3A
Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation. Promoting the social contract with patients to ensure they have affordable access to critical innovative medicines.
Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases. Protecting patients from demonstrations, regulations, and rules that would limit access to life-saving medicines.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · fourth_quarter · Q4
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases. Protecting patients from demonstrations, regulations, and rules that would limit access to life-saving medicines.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · third_quarter · Q3
Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases. Protecting patients from demonstrations, regulations, and rules that would limit access to life-saving medicines.
Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · second_quarter · Q2
Patent Reform Proposals; Patent Settlement Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.
Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations.
Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · first_quarter · Q1
Medicare and Medicaid Provisions reimbursement; Agriculture, Rural Development, Food and Drug Administration Appropriations
Junk Fax regulations and interpretations, and rule promulgations
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2015 · fourth_quarter · Q4
Patent Reform Proposals; Patent Settlement Proposals.
Drug safety and efficacy; bioequivalence.
Tax Policy including changes to corporate tax structure
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2015 · third_quarter · Q3
Drug safety and efficacy; bioequivalence.
Tax Policy including changes to corporate tax structure
Medicare and Medicaid Provisions reimbursement; Agriculture, Rural Development, Food and Drug Administration Appropriations
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2015 · second_quarter · Q2
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Tax Policy including changes to corporate tax structure
Junk Fax regulations and interpretations, and rule promulgations
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2015 · first_quarter · Q1
Tax Policy including changes to corporate tax structure
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues
Junk Fax regulations and interpretations, and rule promulgations
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2014 · fourth_quarter · Q4
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues
Drug Labeling
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2014 · third_quarter · Q3
Junk Fax regulations and interpretations, and rule promulgations
Junk Fax regulations and interpretations, and rule promulgations
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2014 · second_quarter · Q2
Deficit Reduction Act (P.L. 109-171): Medicare and Medicaid Provisions Appropriations Agriculture, Rural Development, Food and Drug Administration.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues
Junk Fax regulations and interpretations, and rule promulgations
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation. Promoting the social contract with patients to ensure they have affordable access to critical innovative medicines.
Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace
Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.
Patent Reform Proposals. Patent Settlement Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.
Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace
Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.
Patent Reform Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.
Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.
Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation. Promoting the social contract with patients to ensure they have affordable access to critical innovative medicines.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Patent Reform Proposals. Patent Settlement Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.
Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.
Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.
Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation. Promoting the social contract with patients to ensure they have affordable access to critical innovative medicines.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016.
Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace
Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Drug Labeling Drug Importation Track and Trace
Drug safety and efficacy; bioequivalence.
Tax Policy including changes to corporate tax structure
Patent Reform Proposals; Patent Settlement Proposals.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Medicare and Medicaid Provisions reimbursement; Agriculture, Rural Development, Food and Drug Administration Appropriations
Drug Labeling Drug Importation Track and Trace
Junk Fax regulations and interpretations, and rule promulgations
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Patent Reform Proposals; Patent Settlement Proposals.
Drug Labeling Drug Importation Track and Trace
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues
Junk Fax regulations and interpretations, and rule promulgations
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues
Deficit Reduction Act (P.L. 109-171): Medicare and Medicaid Provisions Appropriations Agriculture, Rural Development, Food and Drug Administration.
Drug Labeling
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Deficit Reduction Act (P.L. 109-171): Medicare and Medicaid Provisions Appropriations Agriculture, Rural Development, Food and Drug Administration.
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
Drug Labeling
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Tax policy implications
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Deficit Reduction Act (P.L. 109-171): Medicare and Medicaid Provisions Appropriations Agriculture, Rural Development, Food and Drug Administration.
Junk Fax regulations and interpretations, and rule promulgations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Deficit Reduction Act (P.L. 109-171): Medicare and Medicaid Provisions Appropriations Agriculture, Rural Development, Food and Drug Administration.
Drug Labeling
Tax policy implications
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Drug Labeling
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills
Filing targets: HOUSE OF REPRESENTATIVES, SENATE